Second-line treatment with FOLFIRI/ramucirumab delays disease progression and extends overall survival in patients with metastatic colorectal cancer

New findings from the international RAISE phase III study of 1,072 patients with metastatic colorectal cancer (mCRC) whose disease progressed on or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, indicate that a combination of ramucirumab and FOLFIRI provides an overall survival (OS) advantage over standard second-line treatment with FOLFIRI alone. On average, patients treated with the ramucirumab combination lived six weeks longer than those treated with FOLFIRI plus placebo. The study was presented at 2015 Gastrointestinal Cancers Symposium (15-17 January 2015, San Francisco, USA). Read more here.